Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2024
2023
2022
2021
2020
2019

2021.08.19

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)

2021.08.12

Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board

2021.07.22

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

2021.07.07

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million

2021.06.16

Adagene Announces Inclusion in FTSE Russell Indexes

Pagination

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Current page 12
Page 13
Page 14
Page 15
Page 16
Next page
Last page

Displaying 56 - 60 of 79

Shareholder Tools

© 2024 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn